REMOTE-ACS: Rehabilitation Exercise With MObile Technology and Education After Acute Coronary Syndrome

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05385341
Collaborator
(none)
392
1
2
6.9
56.5

Study Details

Study Description

Brief Summary

Despite a clear indication of grade Ia, cardiac rehabilitation (CR) is dramatically underutilized after acute coronary syndrome with less than 30% of patients addressed in France. Mobile technology has the potential to overcome barriers to access to cardiac rehabilitation and may be a useful tool for increasing participation. However, studies have to prove this type of care is as effective as traditional center based cardiac rehabilitation.

Condition or Disease Intervention/Treatment Phase
  • Other: Telerehabilitation (Tele RCV)
  • Other: Rehabilitation (RCV)
N/A

Detailed Description

After acute coronary syndrome (ACS), it is recommended to propose a cardiac rehabilitation (CR) program in order to reduce the risk of recidive, to improve the quality of life and to reduce the risk of disabilities. Traditional CR which is most of the time center-based, is underutilized with less than 30% of patients addressed en France. Therefore, Télé-Cardiac Rehabilitation (Télé-RCV) has been developped progressively since the eighties showing comparable efficacity compared with CR concerning physical fitness. The investigative team, had previously published results showing that telephone support guided by accelerometers could improve physical activity. However, In France, device allowing telemonitoring online of heart rate are not available. Moreover, the investigators have not yet developped remote therapeutic education which is proposed in CR programs. Thus, the present study planned to develop and evaluate aTele-RCV solution aimed to monitor exercise training at home and to educate remotely patient after ACS.

The device is an association of a heart rate monitor, a blood pressure testing, a balance linked with a full web secured application connecting patient and caregivers. In the intervention group, Tele-RCV is proposed during 20 sessions containing 2h of exercise training combined with 6h of therapeutic tele-education. In the control group, CR is proposed during 20 sessions with the same volume of exercise training and therapeutic education. After randomisation, patient are allocated to one of the two groups. The evaluation of the primary and secondary outcomes are realized at the beginning, at one month (only walking tests) and at 2 months. A social evaluation is done in parallel to test the acceptability for the Télé-RCV compared with CR.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
392 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Is Tele-rehabilitation an Efficacious Alternative to Traditional Center Based Cardiac Rehabilitation After Acute Coronary Syndrome?
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Mar 31, 2023
Anticipated Study Completion Date :
Mar 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Telerehabilitation (Tele RCV)

Experimental group (Tele-RCV): the treatment will consist of 20 home-based sessions monitored by the REMOTE-ACS device and containing 2 hours/day 5 days/7 of exercise training (the first session in center to form the patient) associated with 8 educative sessions.

Other: Telerehabilitation (Tele RCV)
20 home-based sessions monitored by the REMOTE-ACS device and containing 2 hours/day 5 days/7 of exercise training associated with educative sessions.

Active Comparator: Rehabilitation (RCV)

Group control (RCV) : 20 sessions of cardiac rehabilitation will be realized in a rehabilitation center containing exercise training during 2 hours/day 5 days/7 and educative program.

Other: Rehabilitation (RCV)
20 sessions of cardiac rehabilitation will be realized in a rehabilitation center containing exercise training during 2 hours/day 5 days/7 and educative program.

Outcome Measures

Primary Outcome Measures

  1. Effect analysis 2 month after inclusion [2 months]

    Change of the peak oxygen volume at 2 months after inclusion

Secondary Outcome Measures

  1. Effect analysis 1 month after inclusion [1 month]

    Analysis of change between T0 and 1 month concerning the walking tests : distance traveled in meters

  2. Effect analysis 1 month after inclusion [1 month]

    Analysis of change between T0 and 1 month concerning the number of Tele-RCV or RCV sessions realized

  3. Effect analysis 2 months after inclusion [2 months]

    Analysis of change between T0 and 2 months concerning the walking tests:distance traveled in meters

  4. Effect analysis 2 months after inclusion [2 months]

    Analysis of change between T0 and 2 months concerning the number of Tele-RCV or RCV sessions realized

  5. Health economics criteria [26 months]

    Incremental Cost-effectiveness ratios of the REMOTE-ACS device compared with the traditional cardiac rehabilitation after acute coronary syndrome according to the French national health insurance perspective and 2 months follow-up period.

  6. Health economics criteria [26 months]

    Cost-utility ratios of the REMOTE-ACS device compared with the traditional cardiac rehabilitation after acute coronary syndrome according to the French national health insurance perspective and 2 months follow-up period.

  7. Production cost of the REMOTE-ACS device [26 months]

    Production cost of the REMOTE-ACS device by micro costing, according the hospital perspective

  8. Acceptability of the device [26 months]

    The acceptability will be assessed by a sociological point of view based on collective meeting (with patient and caregivers) and individual questionnaires for the two groups before randomization and after the program only for the Tele-RCV group.

  9. Satisfaction of the device [26 months]

    The satisfaction will be assessed by a questionnaire of satisfaction titled: Cardiovascular rehabilitation program satisfaction questionnaire, with 8 questions, the minimum value is "nothing", and the maximum value is "very important"

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 79 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient with acute coronary syndrome less than 6 months,

  • Addressed to ambulatory cardiac rehabilitation,

  • Equipped with a smartphone compatible with the protocol's application, connected to web

  • Having signed an informed consent,

  • Affiliated to the french national health insurance.

Exclusion Criteria:
  • Incapacity to use application on smartphone,

  • Contraindication to exercise training,

  • Pregnancy,

  • Juridic protection

  • Left ventricular ejection fraction < 45%

  • Significate ventricular arrhythmia (frequent or polymorph PVC during initial exercise testing, ventricular tachycardia or sudden cardiac death at the beginning)

  • Flutter or atrial fibrillation (transient or permanent)

  • Coronary revascularization needing supplementary procedure

  • Residual myocardial ischemia determined by initial exercise testing or alternative testing (nuclear imaging or stress echocardiography)

  • Mini Mental State < 26

  • Patients living alone at home

  • Comorbidities limiting participation to the protocol: kidney dialysis, insulin-requiring diabetes, residuals sequels of central and/or peripheral nervous system injuries

Contacts and Locations

Locations

Site City State Country Postal Code
1 Marc LABRUNEE Toulouse France

Sponsors and Collaborators

  • University Hospital, Toulouse

Investigators

  • Principal Investigator: Marc LABRUNEE, MD, University Hospital, Toulouse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT05385341
Other Study ID Numbers:
  • RC31/18/0474
First Posted:
May 23, 2022
Last Update Posted:
May 23, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Toulouse
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 23, 2022